Insulin efsitora alfa for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 12 registered trials.

Why this status

  1. 8 Mar 2022: Trial started, NCT05275400
  2. 11 Mar 2022: Trial registered, NCT05275400
  3. 5 May 2022: Trial registered, NCT05362058
  4. 3 Jun 2022: Trial started, NCT05362058
  5. 18 Jul 2022: Trial registered, NCT05462756
  6. 11 Aug 2022: Trial started, NCT05462756
  7. 22 Dec 2022: Trial registered, NCT05662332
  8. 14 Jan 2023: Trial started, NCT05662332

The trials

NCT02942914: A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

State
Completed
Phase
Phase 1
People
80 taking part
Started
20 Dec 2016
Primary completion
18 Oct 2017
Arms
LY3209590
Results
None posted
  1. 24 Oct 2016: Trial registered
  2. 20 Dec 2016: Trial started
  3. 18 Oct 2017: Trial completed

NCT03367377: A Study of LY3209590 in Participants With Type 2 Diabetes

State
Completed
Phase
Phase 1
People
70 taking part
Started
3 Jan 2018
Primary completion
3 Oct 2018
Arms
LY3209590
Results
None posted
  1. 8 Dec 2017: Trial registered
  2. 3 Jan 2018: Trial started
  3. 3 Oct 2018: Trial completed

NCT03736785: A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 2
People
399 taking part
Started
15 Nov 2018
Primary completion
18 Feb 2020
Arms
LY3209590 Algorithm 1, LY3209590 Algorithm 2
Results
Posted on the registry
Papers
doi:10.1016/s2213-8587(22)00388-6
  1. 9 Nov 2018: Trial registered
  2. 15 Nov 2018: Trial started
  3. 18 Feb 2020: Trial completed
  4. 8 Mar 2021: Trial results posted

NCT04450394: A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 2
People
278 taking part
Started
1 Jul 2020
Primary completion
8 Oct 2021
Arms
LY3209590 Algorithm 1 (Paper), LY3209590 Algorithm 2 (Digital)
Results
Posted on the registry
Papers
doi:10.2337/dc22-2396
  1. 29 Jun 2020: Trial registered
  2. 1 Jul 2020: Trial started
  3. 8 Oct 2021: Trial completed
  4. 2 Nov 2022: Trial results posted

NCT04957914: A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 1
People
54 taking part
Started
14 Jul 2021
Primary completion
17 Oct 2022
Arms
LY3209590 (Period 2)
Results
None posted
Papers
doi:10.1007/s13300-024-01605-7
  1. 12 Jul 2021: Trial registered
  2. 14 Jul 2021: Trial started
  3. 17 Oct 2022: Trial completed

NCT05275400: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

State
Completed
Phase
Phase 3
People
986 taking part
Started
8 Mar 2022
Primary completion
15 May 2024
Arms
500 U/mL - Insulin Efsitora
Results
Posted on the registry
Papers
doi:10.1007/s13300-025-01833-5, doi:10.1007/s13300-026-01902-3, doi:10.1016/j.diabres.2026.113586, doi:10.1016/s0140-6736(25)01044-x
  1. 8 Mar 2022: Trial started
  2. 11 Mar 2022: Trial registered
  3. 15 May 2024: Trial completed
  4. 3 Jun 2025: Trial results posted

NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

State
Completed
Phase
Phase 3
People
928 taking part
Started
3 Jun 2022
Primary completion
10 Apr 2024
Arms
500 U/mL - Insulin Efsitora Alfa
Results
Posted on the registry
Papers
doi:10.1007/s13300-025-01833-5, doi:10.1007/s13300-026-01860-w, doi:10.1056/nejmoa2403953
  1. 5 May 2022: Trial registered
  2. 3 Jun 2022: Trial started
  3. 10 Apr 2024: Trial completed
  4. 16 May 2025: Trial results posted

NCT05462756: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

State
Completed
Phase
Phase 3
People
730 taking part
Started
11 Aug 2022
Primary completion
27 Feb 2024
Arms
500 U/mL - Insulin Efsitora
Results
Posted on the registry
Papers
doi:10.1007/s13300-025-01833-5, doi:10.1016/j.diabres.2026.113586, doi:10.1016/s0140-6736(25)01069-4
  1. 18 Jul 2022: Trial registered
  2. 11 Aug 2022: Trial started
  3. 27 Feb 2024: Trial completed
  4. 27 Apr 2025: Trial results posted

NCT05596747: A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 1
People
31 taking part
Started
30 Nov 2022
Primary completion
10 Oct 2023
Arms
LY3209590
Results
None posted
Papers
doi:10.1007/s12325-026-03678-1
  1. 27 Oct 2022: Trial registered
  2. 30 Nov 2022: Trial started
  3. 10 Oct 2023: Trial completed

NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

State
Completed
Phase
Phase 3
People
795 taking part
Started
14 Jan 2023
Primary completion
19 Jul 2024
Arms
Insulin Efsitora Alfa
Results
Posted on the registry
Papers
doi:10.1007/s13300-025-01833-5, doi:10.1056/nejmoa2502796
  1. 22 Dec 2022: Trial registered
  2. 14 Jan 2023: Trial started
  3. 19 Jul 2024: Trial completed
  4. 6 Aug 2025: Trial results posted

NCT06169982: A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

State
Completed
Phase
Phase 1
People
56 taking part
Started
7 Dec 2023
Primary completion
18 Jul 2024
Arms
LY3209590
Results
None posted
  1. 7 Dec 2023: Trial started
  2. 14 Dec 2023: Trial registered
  3. 18 Jul 2024: Trial completed

NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

State
Completed
Phase
Phase 1
People
15 taking part
Started
10 Oct 2024
Primary completion
2 Jan 2026
Arms
LY3209590
Results
None posted
  1. 12 Apr 2024: Trial registered
  2. 10 Oct 2024: Trial started
  3. 2 Jan 2026: Trial completed

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.